

Major Depressive Disorder (MDD) in Children under Age 6

Level 0

Comprehensive assessment. Refer to *Principles of Practice* on page 5.



Level 1

Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian depression and referral for treatment if present.



Level 2

If poor response to psychosocial treatment after 6 to 9 months, re-assess diagnosis, primary care giver response to treatment, and/or consider switching to a different or more intensive psychosocial treatment. Consider child psychiatric consultation or second opinion.

Under 3 years, refer to *Principles of Practice* on page 5.



Level 3

If depression is severe, or there is continued poor response to psychosocial treatment alone, consider combination treatment with fluoxetine and concurrent psychosocial treatment.

- ◆ Fluoxetine — 4 to 5 years old
 - ◇ Maximum dose: 5 mg/day
 - ◇ Discontinuation trial after 6 months of any effective medication treatment with gradual downward taper.
 - ◇ **Monitor for behavioral disinhibition and suicidality.** Behavioral disinhibition is defined as impulsive, sensation seeking behaviors and lack of self-regulation.

Not Recommended:

- ◆ The use of medication without psychosocial treatment.
- ◆ Use of tricyclic antidepressants (TCAs) or paroxetine.

Note: In preschool children, MDD is very rare (point prevalence is thought to be 0.5%).

Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old

Level 0

Assessment

- ◆ Screening using multi-informant, validated rating scales that include depression and screening for comorbidity (other psychiatric and medical conditions):
 - ◇ Center for Epidemiological Studies Depression Scale for Children Patient Health Questionnaire (CES-DC)
 - ◇ Patient Health Questionnaire-9 (PHQ-9)
 - ◇ Pediatric Symptom Checklist (PSC)

Note: The above scales are available at <http://medicaidmentalhealth.org/>.
- ◆ Perform risk assessment: Specific screen for harm to self or others and access to firearms, knives/sharps, and other lethal means such as alcohol, prescription and non-prescription medications.
- ◆ Evaluate sleep hygiene, diet, and exercise.
- ◆ Address environmental stressors such as abuse, bullying, conflict, functioning at school, peer relationships, family dysfunction, and caregiver depression.
- ◆ **Establish a safety plan:**
 - ◇ Removal of firearms, knives/sharps, and other lethal means such as alcohol, prescription and non-prescription medications.
 - ◇ **Develop an emergency action plan:**
 - Provide adolescents with mutually agreeable and available emergency numbers and contacts.
 - Engage a concerned third party familiar with the adolescent.
- ◆ Positive screen: DSM-5 based interview evaluation.
- ◆ Consider medical reason for depression [e.g., hypothyroidism, B12/folate deficiency, anemia, malnutrition (with or without eating disorder), chronic disorder (diabetes, asthma, inflammatory bowel disease, juvenile rheumatoid disease, infectious mononucleosis, etc.)].
- ◆ Rule out iatrogenic etiology of depression (i.e., medication side effects/interactions).
- ◆ Evaluate past psychiatric and medical history, previous treatment, family conflict and current depression of family and caregivers, bullying, abuse, peer conflict, school issues, and substance abuse.
- ◆ Consider and rule out presence of bipolar depression. Pointers: Prior (hypo) mania, family history of bipolar disorder, atypical depression with reverse neurovegetative signs, seasonal affective component, brief and recurrent episodes, and melancholic depression in prepubertal child.

Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old *(continued)*

Level 0 *(continued)*

- ◆ Track outcomes using empirically validated tools. Refer to DSM-5 Severity Measure for Depression, Child Age 11–17 available and Child Depression Inventory (CDI) available at <http://www.medicaidmentalhealth.org/>.

Note: The Child Depression Inventory is not available in the public domain.

Always monitor for:

- ◆ Emergence or exacerbation of suicidality and balance the risk–benefit profile of antidepressants during the acute treatment phase.
- ◆ Behavioral activation (e.g., difficulty falling asleep, increased motor activity, increased talkativeness)
- ◆ Adverse events
- ◆ Treatment adherence
- ◆ Treatment or inherently emergent comorbidity
- ◆ Potential development of (hypo)mania






Level 1


Initial treatment plan

- ◆ Active support: 6 week trial (if mild symptoms).
 - ◇ Components of active support must include psychosocial interventions and psychoeducation and may include: Self-help materials, active listening/relationship building, school involvement, mood monitoring, pleasant activities, cognitive restructuring, family conflict reduction, sleep hygiene, and exercise.

Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old *(continued)*

	<p>Level 2</p> <p>Reassess diagnosis first (e.g., bipolar disorder), rule out psychostimulant or substance abuse related psychosis. Targeted treatments if symptoms are moderate to severe, impairment continues, and/or no response to active support. Start with Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), depression-specific behavioral family therapy.</p> <ul style="list-style-type: none"> ◆ 2a. Fluoxetine or combination of CBT or IPT psychotherapy with fluoxetine. ◆ 2b. May consider use of escitalopram for age 12 and above. <p>Qualifiers:</p> <ul style="list-style-type: none"> ◆ Mild: Psychosocial interventions only. ◆ Moderate/Severe: Combination of CBT or IPT psychotherapy with fluoxetine. ◆ Psychosis: SSRIs (fluoxetine, escitalopram) plus consider antipsychotics (adult data only). Careful evaluation of symptoms to determine the degree of psychosis to warrant the use of antipsychotics. ◆ Comorbidity: Combination of CBT or IPT psychotherapy with fluoxetine; treat comorbidity. ◆ Suicidality: Intensify surveillance and follow-up; combination therapy with CBT or IPT psychotherapy if on antidepressant only or remove antidepressant if otherwise ineffective; if chronic, consider lithium augmentation.
	<p>Level 3</p> <p>Inadequate response</p> <ul style="list-style-type: none"> ◆ If no clinical response to the medication utilized in Level 2, switch to another medication listed above.
	<p>Level 4</p> <p>Poor or non-response</p> <ul style="list-style-type: none"> ◆ Refer to mental health specialist. ◆ Re-assess diagnosis (bipolar disorder, substance use disorder, anxiety disorders, PTSD), rule out medical condition (e.g., hypothyroidism), or medication side effects. ◆ Increase psychosocial intervention and medication dose if tolerated. ◆ Augment with alternate psychosocial intervention (either CBT or IPT). ◆ Consider change in level of care (treatment setting and interventions based on severity of illness). ◆ For milder form and/or seasonal affective symptoms with light sensitivity, consider bright light therapy.

Major Depressive Disorder (MDD) in Children and Adolescents Ages 6 to 17 Years Old (continued)

	<p>Level 5</p> <p>If poor or non-response to Level 4 interventions</p> <ul style="list-style-type: none">◆ Switch previously used SSRIs to sertraline, citalopram, bupropion or venlafaxine, especially in those who do not have access to psychotherapy or have not responded to non-pharmacological interventions.◆ Consider augmentation of SSRI with bupropion, thyroxine, lithium, buspirone, mirtazapine, aripiprazole, quetiapine, or risperidone (adult data only).◆ If psychotic/severe: ECT (for adolescents). <p>Notes:</p> <ul style="list-style-type: none">◆ Factors favoring maintenance treatment (at any Level):<ul style="list-style-type: none">◇ Partial response◇ Prior relapse◇ Suicidality◇ Comorbidity risk for relapse◇ Environmental risk for relapse◇ Family history of relapsing/recurrent major depression◇ Lack of return to full premorbid functioning◆ Maintenance treatment: 9 to 12 months.◆ After maintenance treatment: If stable, at level of premorbid functioning, and no anticipated increase in stressors, consider discontinuation trial over 3 to 4 months.◆ Venlafaxine: Caution due to robust evidence of a significantly increased risk for suicidal behavior or ideation <p><i>Note on pharmacogenomic testing: The current evidence does not support pharmacogenomic testing in routine psychiatric clinical practice.</i></p>
---	---

For a full list of references, visit <http://medicaidmentalhealth.org/>.

Major Depressive Disorders (MDD) Resources

SELECTED RESOURCES

■ Guides for Parents:

- ◆ If Your Adolescent Has Depression or Bipolar Disorder: An Essential Resource for Parents (Evans, 2005)
- ◆ Adolescent Depression: A Guide for Parents (Mondimore and Kelly, 2015)
- ◆ Depression and Your Child: A Guide for Parents and Caregivers (Serani, 2013)

■ Workbooks for Youth:

- ◆ Think Good, Feel Good: A Cognitive Behavior Therapy Workbook for Young People (Stallard, 2002)
- ◆ How to Get Unstuck from the Negative Much: A Kid's Guide to Getting Rid of Negative Thinking (Sullivan, 2013)

■ Books for Children:

- ◆ What to Do When You Grumble Too Much: A Kid's Guide to Overcoming Negativity (Huebner, 2007)
- ◆ The Princess and the Frog: A Story for Children with Depression (Jones, 2015)

■ Relevant Websites:

- ◆ American Academy of Child and Adolescent Psychiatry (AACAP) Depression Resource Center: https://www.aacap.org/aacap/Families_and_Youth/Resource_Centers/Depression_Resource_Center/Home.aspx
- ◆ National Institute of Mental Health—Depression in Children and Adolescents: The National Institute of Mental Health Site on Depression in Children and Adolescents <http://www.nimh.nih.gov/health/topics/depression/depression-in-children-and-adolescents.shtml>
- ◆ National Alliance of the Mentally Ill (NAMI): National Alliance of the Mentally Ill (NAMI) <https://www.nami.org/>
- ◆ Depression and Bipolar Support Alliance: Depression and Bipolar Support Alliance <http://www.dbsalliance.org/site/PageServer?pagename=home>
- ◆ Teen Mental Health Website: <http://teenmentalhealth.org/care/parents/>

Note: Above resources and website links were updated at the time of publication.

For a full list of references, visit <http://medicaidmentalhealth.org/>.